Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 207-856-6 | CAS number: 498-15-7
Endpoint summary
Administrative data
Description of key information
In GLP in vitro studies using Episkin model, delta-3-carene led to a cell viability of 29.8 ± 1.3 %.
In a GLP in vivo eye irritation study, delta-3-carene was not irritating to eyes.
Key value for chemical safety assessment
Skin irritation / corrosion
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (irritating)
Eye irritation
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not irritating)
Respiratory irritation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
In GLP in vitro studies using Episkin model, exposure of epidermis to delta-3-carene for 15 min lead to a cell viability, measured by MTT conversion, of 29.8 ± 1.3 %.
In a recent GLP in vivo eye irritation study on delta-3-carene performed according to OECD Guideline 405, instillation of delta-3-carene resulted in moderate redness of the conjunctivae associated with severe chemosis in all treated animals after 1 hour of instillation. The irritation completely resolved within 8 days. Mean individual scores at 24, 48 and 72 h after exposure for the 3 rabbits were 0, 0, 0 for cornea score; 0, 0, 0 for iris score; 2, 1.33, 1.33 for conjunctivae score and 2, 1.33, 1 for chemosis score.
Justification for selection of skin
irritation / corrosion endpoint:
Only one study available on the registered substance
Justification for selection of eye irritation endpoint:
Only one study available on the registered substance
Effects on skin irritation/corrosion: irritating
Justification for classification or non-classification
As the percentage of cell viability obtained in Episkin model was ≤ 50 % for delta-3-carene, it is considered to be irritating to skin. Under the test conditions, delta-3-carene is classified as irritating to skin, R38, according to the criteria of Annex VI to the Directive 67/548/EEC and category 2 according to CLP Regulation (EC) N° 1272/2008.
delta-3 -Carene gave reversible irritating effects on rabbit eyes with irritation scores not high enough to lead to classification according to the criteria of Directive 67/548/EEC and CLP Regulation (EC) N° 1272/2008. Therefore, delta-3-carene is not classified for eye irritation according to Directive 67/548/EEC and CLP Regulation (EC) N° 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
